Australia Consults On New Guidelines For Reimbursement Listing
This article was originally published in SRA
Executive Summary
Clearer guidance for pharmaceutical companies on how to apply for a reimbursement listing for new drugs has moved a step nearer after the Australian government released the draft revised Pharmaceutical Benefits Advisory Committee (PBAC) guidelines1 for comment by April 5, 2016.